BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220919
DTEND;VALUE=DATE:20220924
DTSTAMP:20260516T033509
CREATED:20220317T083147Z
LAST-MODIFIED:20220317T083147Z
UID:33597-1663545600-1663977599@www.pharmajournalist.com
SUMMARY:7th CAR-TCR Summit
DESCRIPTION:Back to Boston with a bang! With 1\,500 CAR and TCR developers\, 200 speakers\, 150 live presentations\, 20 hours of networking and more surprises in store\, the 7th CAR-TCR Summit will be the BIGGEST ever. \nGain end-to-end insights from industry giants and the innovators bringing disruptive technologies from bench to bedside and from vein to vein. \nDiscuss everything from novel allogeneic approaches with enhanced safety considerations\, the latest in vivo gene engineering techniques\, and advances in CMC and analytics to ensure the development of high-quality cell products. \nWith your industry reuniting in-person for the first time since 2019 to discuss leveraging the powerful potential of iPSC platforms\, learnings from our successes and pitfalls\, and manufacturing automation innovations for large scale consistent production\, you can’t afford to miss the 7th Annual CAR-TCR Summit as we bring you more speakers\, more content and more exclusive insights than ever before! \nTo know more visit: https://ter.li/km5zwy
URL:https://www.pharmajournalist.com/event/7th-car-tcr-summit/
LOCATION:Boston\, MA
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220920
DTEND;VALUE=DATE:20220923
DTSTAMP:20260516T033509
CREATED:20220519T110535Z
LAST-MODIFIED:20220908T090420Z
UID:34139-1663632000-1663891199@www.pharmajournalist.com
SUMMARY:mRNA Process Development & Manufacturing Summit
DESCRIPTION:The mRNA Process Development & Manufacturing Summit will be taking place in-person in Boston\, MA this month (September 20 – 22\, 2022). The only conference roadmap to accelerate mRNA drug substance process scale up and manufacturing! \nThis conference will showcase the pioneering work of 30+ global leaders across 3 days of immersive content sharing new data\, allowing you to stay ahead of the curve. \nIf you and your team are looking to learn how to overcome mRNA process scale up and manufacturing hurdles towards regulatory harmonization by optimizing in vitro transcription\, purification\, and analytical validation of your mRNA drug substance\, then you should attend this dedicated industry forum to see the outlook to this advancing and dynamic field. \nMultiple functions from 75+ leading companies and their teams have already registered\, here’s just a snapchat: \n\nDirector – Business Development mRNA Therapeutics\nSenior Director – Manufacturing Science & Technology\nHead of Quality\nPrincipal Applications Scientist – mRNA\nDirector – Formulation and Drug Delivery\nPrincipal Scientist – Early Bioprocess\nSenior Process Development Associate – mRNA\nGroup Leader (RNA Reagents) – Production\nDownstream Scientist – Technical R&D\nScientist II – Analytical Development\nDirector – RNA Therapeutics Development R & D\nDirector – CMC RNA Vaccines Biopharmaceutical Development\nAssociate Director – Drug Substance\nSenior Director – CMC Reg Affairs Regulatory\n\nWith very limited passes remaining\, register today and be part of the conversation. \nTo know more visit: https://ter.li/9v5h9k
URL:https://www.pharmajournalist.com/event/mrna-process-development-manufacturing-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220920
DTEND;VALUE=DATE:20220923
DTSTAMP:20260516T033509
CREATED:20220607T100621Z
LAST-MODIFIED:20220607T100621Z
UID:34368-1663632000-1663891199@www.pharmajournalist.com
SUMMARY:2nd NSCLC Drug Development Summit
DESCRIPTION:Advances in molecular and immunohistochemical techniques have ushered the NSCLC space into an exciting era of personalized medicine and improved outcomes – and a plethora of novel therapies are now in clinical development. Despite this\, and whether patients fit into one of the actionable alteration subtypes of NSCLC or not\, most will progress and/or develop resistance to currently available treatments. \nNSCLC remains one of the highest tumor indications of unmet clinical need\, with prevalence only set to increase. Focusing from late-line through to early-line\, this conference will address how to supercharge your pipeline through implementing smart drug design; expert translational medicine; advanced trial design and patient recruitment; and evidence-based combination and sequencing rationale specific to NSCLC. \nThe 2nd NSCLC Drug Development Summit returns as the only industry-led forum for large biopharma\, biotech and academic leaders to address mechanisms of drug resistance\, spearhead progress in molecular subtyping and define practice-changing drug sequencing and combinations for the largest solid tumor indication. \nWe will be focusing on: \n\nRefining molecular testing of NSCLC tumors and making next-generation sequencing tools more accessible in the clinical setting\nInvestigating novel immune checkpoints and checkpoint inhibitor sequencing or combinations with surgery\, chemo and/or radiotherapy where applicable\, to define therapeutic options with better safety and efficacy outcomes in second line or beyond\nOvercoming resistance mechanisms and patient progression after TKI treatment approaches for NSCLC tumors with actionable alterations\nProviding clarity on tumor biopsy testing guidelines to promote effective personalized treatment of patients\nIdentifying truly transformative investigational drugs for use in the early vs. late-stage NSCLC setting and cut through the noise of increasingly complex therapeutic options\nExploring trial design challenges to watch out for and tips for patient inclusion/exclusion criteria\n\nJoin the NSCLC Summit for 3 jam-packed days of presentations\, panel discussions and interactive workshops with over 20 expert industry speakers. \nThere has never been a more important time to rally together to defeat NSCLC and radically change patients lives. \nTo know more visit: https://bit.ly/3mpftud
URL:https://www.pharmajournalist.com/event/2nd-nsclc-drug-development-summit/
LOCATION:Boston\, MA (venue TBC)
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220920
DTEND;VALUE=DATE:20220922
DTSTAMP:20260516T033509
CREATED:20220720T075747Z
LAST-MODIFIED:20220720T075747Z
UID:34728-1663632000-1663804799@www.pharmajournalist.com
SUMMARY:Reuters Events: Cell & Gene Therapy USA 2022
DESCRIPTION:Co-create a commercial toolkit that enables suitable\, scalable and sustainable growth.  \nWith over 20 CGTs projected to be approved by 2025\, it’s clear that there are huge commercial and medical opportunities for precision medicine. But despite this unprecedented growth\, unstable infrastructure\, lack of standardization and novel scientific nuance means that there is still no industry blueprint for successful commercialization. \nTo realize this potential\, precision medicine trailblazers must share lessons of launch success and overcome pain points to allow pharma to reinforce frameworks across manufacturing\, market access and reimbursement to build infallible launch strategies across the board. Commercialization networks must go even further\, transforming our healthcare system to guarantee scalable and sustainable growth.     \nDon’t get left behind.   \nJoin us at Reuters Events: Cell and Gene Therapy USA where we have leaders from industry front runners to share their successes and pitfalls. With 30+ speakers\, 5 case-studies and over 1500+ fellow CGT attendees – we will pioneer a new gold standard for commercialization\, readying the world for CGT as a frontline treatment. \nTo know more visit: https://bit.ly/3oepDP3
URL:https://www.pharmajournalist.com/event/reuters-events-cell-gene-therapy-usa-2022/
LOCATION:Virtual
ORGANIZER;CN="Reuters Events":MAILTO:daisy.beale@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220921
DTEND;VALUE=DATE:20220923
DTSTAMP:20260516T033509
CREATED:20220404T083554Z
LAST-MODIFIED:20220404T083554Z
UID:33687-1663718400-1663891199@www.pharmajournalist.com
SUMMARY:Oligonucleotide Therapeutics and Delivery Conference 2022
DESCRIPTION:Part of the 13th annual RNA Therapeutic series of events\nSMi’s 2nd Annual Conference \nOligonucleotide Therapeutics and Delivery Conference 2022\nDate: 21st – 22nd September 2022\nLocation: London\, UK\nWebsite: www.oligonucleotide.co.uk/PharmaJournalist \nAdvancements in extra-hepatic delivery of oligonucleotides \nThe Oligonucleotide Therapeutics and Delivery conference reveals the latest in oligonucleotide discovery and delivery\, with presentations on targeted delivery mechanisms\, oligonucleotide chemistries and important clinical advances. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of oligonucleotides with case studies surrounding the discovery and development of oligonucleotide therapeutics as well as CMC and regulatory standpoints. The two-day conference will bring you high-quality insights and industry connections on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. \nEstablished on the success of our RNA Therapeutics series\, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments. \nBenefits of attending: \n\nListen to case studies presenting on pre-clinical and clinical research in areas such as oncology and what can be learned for future clinical trials\nDeepen your understanding of oligonucleotide therapeutic delivery and explore the latest innovations in extrahepatic oligonucleotide delivery and target specificity\nUnderstand the regulatory and CMC environment surrounding oligonucleotide therapeutic development\nExplore developments in oligonucleotide chemistries and examine developments in novel applications of antisense oligonucleotides and siRNA\nEngage in the latest innovations in oligonucleotide therapeutics such as utilising AI machine learning to drive the discovery of novel therapeutics\n\nPlus\, two interactive half day pre-conference workshops on 20th September 2022: \n\nOligonucleotide Therapies- Overcoming The Challenges Of Delivery led by Nick Lench\, Executive Director\, NATA\, Martin Kerr\, Head of Business Development & Partnerships\, Nucleic Acid Therapy Accelerator\, Ritwick Sawakar\, MRC Investigator\, MRC Toxcology Unit\, University Of Cambridge\nManaging CMC Activities For The Development Of Oligonucleotide Therapeutics led by Mia Kiistala\, CEO/Owner/Principal Consultant\, Aurora CMC Consulting \n\nCHAIRS FOR 2022: \n\nEkkehard Leberer\, Senior Life Sciences Consultant\, Elbicon\njimmy Weterings\, Principal Scientist\, AstraZeneca \n\nFEATURED 2022 SPEAKERS INCLUDE:  \n\nShalini Anderson\, Vice President Oligonucleotide Discovery\,AstraZeneca\nHeinrich Haas\, Vice President RNA Formulation & Drug Delivery\, BioNTech\nTamar Grossman\, Global Head of RNA and Targeted Therapeutics\, Janssen pharmaceuticals\nSarahTabrizi\,Director of UCL Huntington’s disease centre\, UCL Institute of Neurology\nMacarena Hernandez-Jimenez\, Chief Scientific Officer\, AptaTargets\nDavid Evans\, Chief Scientific Officer\, Sirnaomics\nNick Lench\, Executive Director\, Nucleic Acid Therapy Accelerator\nBart Anderson\,Senior Director of R&D\, Exicure\n\nWho should attend: \nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of: \n\nRNA Biology/Discovery\nNovel Therapeutic Modalities\nInnovation Technologies\nC-level Scientific Executives\nFormulation and Drug Delivery\nClinical Research and Development\nCell Biology\n\nEARLY-BIRD RATES: \n\nBOOK BY 29TH APRIL AND SAVE £400\nBOOK BY 31ST MAY AND SAVE £300\nBOOK BY 30TH JUNE AND SAVE £200\n\nAdditional Contact Info: \nT: +44 (0)20 7827 6154 \nE: ngaloria@smi-online.co.uk \nLinkedIn: SMi Pharma \nTwitter: @SMiPharma | #SMiOligonucleotides  \nKeywords: \nSmall interfering RNA\, siRNA\, Antisense therapy\, DNA\, RNA\, nucleic acid\, mRNA\, Micro RNA\, RNA-induced silencing complex\, RISC\, Aptamers\, oligonucleotide\, peptide molecules\, Immunogenicity\, Drug pipeline\, short interfering RNA\, silencing RNA\, RNA interference\, RNAi\, mRNA degradation \nHashtags:  \n#SmallinterferingRNA\, #siRNA\, #Antisensetherapy\, #DNA\, #RNA\, #nucleicacid\, #mRNA\, #MicroRNA\, #RNAinducedsilencingcomplex\, #RISC\, #Aptamers\, #oligonucleotide\, #peptidemolecules\, #Immunogenicity\, #Drugpipeline\, #shortinterferingRNA\, #silencingRNA\, #RNAinterference\, #RNAi\, #mRNAdegradation
URL:https://www.pharmajournalist.com/event/oligonucleotide-therapeutics-and-delivery-conference-2022/
LOCATION:London\, UK
ORGANIZER;CN="SMi Events":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
END:VCALENDAR